retatrutide type 2 diabetes phase 2 trial A new weight-loss drug called is generating excitement after clinical participants lost an average of 30% of their body weight, results that rival or even exceed weight-loss surgery. Researchers also Efficacy and safety of retatrutide,
Description
References Blundell, J., Finlayson, G., Axelsen, M., et al
00967-0/asset/1cda1e69-507e-47d1-ad73-620bcd1cbb66/main.assets/gr2_lrg.jpg)
V., Samet, J

Short-acting drugs primarily lower postprandial blood glucose levels by slowing gastric emptying, while long-acting GLP-1 RAs are more effective at reducing fasting blood glucose levels, mainly by promoting insulin secretion and inhibiting glucagon release

Cummings DM, Lutes LD, Littlewood K, Solar C, Carraway M, Kirian K, et al

doi: 10.1007/s13300-020-00981-0 [DOI] [PMC free article] [PubMed] [Google Scholar] 21.Finan B, Ma T, Ottaway N, et al
